natgillin/translations-raw huggingface dataset:
ANNEX III LABELLING AND PACKAGING LEAFLET 
OZNAČEVANJE IN NAVODILO ZA UPORABO
Each hard capsule contains 150 mg pregabalin. 
Ena trda kapsula vsebuje 150 mg pregabalina.
Each hard capsule contains 100 mg pregabalin. 
Ena trda kapsula vsebuje 100 mg pregabalina.
Lyrica 75 mg hard capsules Pregabalin 
Lyrica 75 mg trde kapsule pregabalin
Stevens Johnson syndrome, cold sweat Musculoskeletal and connective tissue disorders Common 
Stevens-Johnsonov sindrom, hladen znoj Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti krči mišic, artralgija, bolečine v hrbtu, bolečine v udih, spazem v vratu
Sealed Pack Do not use if box has been opened. 
Če so vidni znaki odprtja, zdravila ne smete uporabiti.
Light orange hard capsules, with “Pfizer” marked on the cap and “PGN 200” on the body. 
Svetlo oranžne trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 200« na telesu kapsule.
Lyrica 50 mg hard capsules 
Lyrica 50 mg trde kapsule
Bottle immediate packaging for 25 mg hard capsules - pack of 200 
Škatla s plastenko za 25 mg trde kapsule - pakiranje po 200
Lyrica 100 mg hard capsules Pregabalin 
Lyrica 100 mg trde kapsule pregabalin
White and light orange hard capsules, with “Pfizer” marked on the cap and “PGN 225” on the body. 
Belo-svetlo oranžne trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 225« na telesu kapsule.
Lyrica 25 mg hard capsules 
Lyrica 25 mg trde kapsule
PVC/Aluminium blisters containing 14, 56, 70 100, or 112 hard capsules. 
PVC/aluminijski pretisni omoti s 14, 56, 70, 100 ali 112 trdimi kapsulami.
Each hard capsule contains 50 mg pregabalin. 
Ena trda kapsula vsebuje 50 mg pregabalina.
Each hard capsule contains 25 mg pregabalin. 
Ena trda kapsula vsebuje 25 mg pregabalina.
Lyrica 200 mg hard capsules Pregabalin 
Lyrica 200 mg trde kapsule pregabalin
White hard capsules, with “Pfizer” marked on the cap and “PGN 25” on the body. 
Bele trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 25« na telesu kapsule.
14 hard capsules 56 hard capsules 70 hard capsules 100 hard capsules 100 x 1 hard capsules 112 hard capsules 
14 trdih kapsul 56 trdih kapsul 70 trdih kapsul 100 trdih kapsul 100 x 1 trda kapsula 112 trdih kapsul
White hard capsules, with “Pfizer” marked on the cap and “PGN 150” on the body. 
Bele trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 150« na telesu kapsule.
PVC/Aluminium blisters containing 14, 56, or 100 hard capsules. 
PVC/aluminijski pretisni omoti s 14, 56 ali 100 trdimi kapsulami.
Carton of blister pack (14, 56 or 100) and perforated unit dose blister pack (100) for 225 mg hard capsules 
Pretisni omot (14, 56 in 100) in perforirani enoodmerni pretisni omot (100) za 225 mg trde kapsule
Immune system disorders Uncommon 
Bolezni imunskega sistema Občasni preobčutljivost
PVC/Aluminium blisters containing 14, 56, 100, or 112 hard capsules. 
PVC/aluminijski pretisni omoti s 14, 56, 100 ali 112 trdimi kapsulami.
14 hard capsules 56 hard capsules 100 hard capsules 100 x 1 hard capsules 
14 trdih kapsul 56 trdih kapsul 100 trdih kapsul 100 x 1 trda kapsula
14 hard capsules 21 hard capsules 56 hard capsules 84 hard capsules 100 hard capsules 100 x 1 hard capsules 112 hard capsules 
14 trdih kapsul 21 trdih kapsul 56 trdih kapsul 84 trdih kapsul 100 trdih kapsul 100 x 1 trda kapsula 112 trdih kapsul
White hard capsules, with “Pfizer” marked on the cap and “PGN 50”on the body. 
Bele trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 50« na telesu kapsule.
300 mg capsules White and orange hard capsules, with “Pfizer” marked on the cap and “PGN 300” on the body. 
Belo-oranžne trde kapsule z oznako »Pfizer« na pokrovčku in »PGN 300« na telesu kapsule.
Lyrica 25 mg hard capsules Pregabalin 
Lyrica 25 mg trde kapsule pregabalin
Hypotension, hypertension, hot flushes, flushing, peripheral coldness Respiratory, thoracic and mediastinal disorders Uncommon 
Redki ascites, pankreatitis, oteklost jezika, disfagija Bolezni jeter, žolčnika in žolčevodov Občasni zvišane vrednosti jetrnih encimov*
14 hard capsules 56 hard capsules 100 hard capsules 100 x 1 hard capsules 112 hard capsules 
14 trdih kapsul 56 trdih kapsul 100 trdih kapsul 100 x 1 trda kapsula 112 trdih kapsul
Carton of blister pack (14, 56, 70, 100, and 112) and perforated unit dose blister pack (100) for 75 mg hard capsules 
Pretisni omot (14, 56, 70, 100 in 112) in perforirani enoodmerni pretisni omot (100) za 75 mg trde kapsule
Lyrica 50 mg hard capsules Pregabalin 
Lyrica 50 mg trde kapsule pregabalin
Lyrica 300 mg hard capsules Pregabalin 
Lyrica 300 mg trde kapsule pregabalin
Blister pack (14, 21, 56, 84, 100, and 112) and perforated unit dose blister pack (100) for 25 mg hard capsules 
Pretisni omot (14, 21, 56, 84, 100 in 112) in perforirani enoodmerni pretisni omot (100) za 25 mg trde kapsule
14 hard capsules 21 hard capsules 56 hard capsules 84 hard capsules 100 hard capsules 100 x 1 hard capsules 
14 trdih kapsul 21 trdih kapsul 56 trdih kapsul 84 trdih kapsul 100 trdih kapsul 100 x 1 trda kapsula
Carton of blister pack (14, 21, 56, 84, 100, and 112) and perforated unit dose blister pack (100) for 25 mg hard capsules. 
Škatla s pretisnim omotom (14, 21, 56, 84, 100 in 112) in perforiranim enoodmernim pretisnim omotom (100) za 25 mg trde kapsule
Pfizer GEP, S.L Tel: +34 91 490 99 00 
Tél: +34 91 490 99 00
In addition, Lyrica is available in an HDPE bottle containing 200 capsules for the 25 mg, 75 mg, 150 mg and 300 mg strengths. 
Poleg tega je zdravilo Lyrica v jakostih 25 mg, 75 mg, 150 mg in 300 mg na voljo v plastenki iz polietilena visoke gostote z 200 kapsulami.
Carton of blister pack (14, 21, 56, 84 and 100) and perforated unit dose blister pack (100) for 50 mg hard capsules 
Škatla s pretisnim omotom (14, 21, 56, 84 in 100) in perforiranim enoodmernim pretisnim omotom (100) za 50 mg trde kapsule
Shellac 
OČkr
Carton of blister pack (14, 56, 100, and 112) and perforated unit dose blister pack (100) for 300 mg hard capsules 
Škatla s pretisnim omotom (14, 56, 100 in 112) in perforiranim enoodmernim pretisnim omotom (100) za 300 mg trde kapsule
Blister pack (14, 21, 56, 84 and 100) and perforated unit dose blister pack (100) for 50 mg hard capsules 
Pretisni omot (14, 21, 56, 84 in 100) in perforirani enoodmerni pretisni omot (100) za 50 mg trde kapsule
Carton of blister pack (14, 56, 100, and 112) and perforated unit dose blister pack (100) for 150 mg hard capsules 
Pretisni omot (14, 56, 100 in 112) in perforirani enoodmerni pretisni omot (100) za 150 mg trde kapsule
Blister pack (14, 56, 100 or 112) and perforated unit dose blister pack (100) for 300 mg hard capsules 
Pretisni omot (14, 56, 100 in 112) in perforirani enoodmerni pretisni omot (100) za 300 mg trde kapsule
Carton of blister pack (21, 84 or 100) and perforated unit dose blister pack (100) for 100 mg hard capsules 
Škatla s pretisnim omotom (21, 84 in 100) in perforiranim enoodmernim pretisnim omotom (100) za 100 mg trde kapsule
Carton of blister pack (21, 84 or 100) and perforated unit dose blister pack (100) for 200 mg hard capsules 
Škatla s pretisnim omotom (21, 84 in 100) in perforiranim enoodmernim pretisnim omotom (100) za 200 mg trde kapsule
Each hard capsule also contains 24.75 mg lactose monohydrate. 
Lyrica 225 mg trde kapsule Ena trda kapsula vsebuje tudi 24,75 mg laktoze monohidrata.
Blister pack (21, 84 or 100) and perforated unit dose blister pack (100) for 100 mg hard capsules 
Pretisni omot (21, 84 in 100) in perforirani enoodmerni pretisni omot (100) za 100 mg trde kapsule
Blister pack (21, 84 or 100) and perforated unit dose blister pack (100) for 200 mg hard capsules 
Pretisni omot (21, 84 in 100) in perforirani enoodmerni pretisni omot (100) za 200 mg trde kapsule
• There have been reports of kidney failure in some patients when taking Lyrica. 
• Pri nekaterih bolnikih, ki so jemali zdravilo Lyrica, so opisani primeri odpovedi ledvic.
Each hard capsule also contains 8.25 mg lactose monohydrate. 
Lyrica 75 mg trde kapsule Ena trda kapsula vsebuje tudi 8,25 mg laktoze monohidrata.
Pregnancy 
smrčanje
You may feel sleepy, confused, agitated, or restless as a result of taking more Lyrica than you should. 
Če ste vzeli večji odmerek zdravila Lyrica, kot bi smeli, se lahko počutite zaspani, zmedeni, tesnobni ali nemirni.
This means that it is similar to one or more ‘reference medicines' already authorised in the European Union (EU). 
To pomeni, da je podobno enemu ali več „referenčnim zdravilom“, ki so že odobrena v Evropski uniji (EU).
An additional infusion, given at least one year after the first one, can be considered if the patient's disease comes back. 
O dodatnem infundiranju, ki se da najmanj eno leto po prvem, se lahko razmisli, če se bolezen pri bolniku ponovi.
This is a long-term disease where the normal process of bone growth is altered, which causes bones to become weakened or deformed. 
Gre za dolgotrajno bolezen, pri kateri je običajni postopek rasti kosti spremenjen, zaradi česar postanejo kosti krhke ali deformirane.
They can also be used to treat the hypercalcaemia caused by tumours. 
Uporablja se lahko tudi za zdravljenje hiperkalciemije, ki jo povzročijo tumorji.
For more information on generic and hybrid medicines, see the question-and-answer document here. 
Za več informacij o generičnih in hibridnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj.
The full EPAR for Zoledronic Acid Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zoledronska kislina Hospira je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This leads to less disease activity in Paget's disease. 
To povzroči, da je Pagetova bolezen manj dejavna.
When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. 
Pri uporabi za preprečevanje zapletov, povezanih z okostjem, je infundiranje mogoče ponoviti vsake tri do štiri tedne, bolniki pa morajo prejemati tudi dodatek kalcija in vitamina D.
Patients must have adequate fluids before and after treatment, and should receive adequate supplements of vitamin D and calcium. 
Bolniki morajo pred zdravljenjem in po njem popiti zadostno količino tekočin ter prejemati ustrezne dodatke vitamina D in kalcija.
For more information about treatment with Zoledronic Acid Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zoledronska kislina Hospira preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic Acid Hospira on 19 November 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Zoledronska kislina Hospira, veljavno po vsej Evropski uniji, izdala 19. novembra 2012.
This is a summary of the European public assessment report (EPAR) for Zoledronic Acid Hospira. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zoledronska kislina Hospira.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic Acid Hospira. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It is available as a concentrate (4 mg/5 ml) to be made up into a solution for infusion (drip) into a vein, and as solutions for infusion (4 mg/100 ml and 5 mg/100 ml). 
Na voljo je kot koncentrat (4 mg/5 ml) za pripravo raztopine za infundiranje (kapalne infuzije) v veno ter kot raztopina za infundiranje (4 mg/100 ml in 5 mg/100 ml).
The CHMP concluded that, in accordance with EU requirements, Zoledronic Acid Hospira has been shown to be comparable to Zometa and Aclasta. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Zoledronska kislina Hospira primerljivo z zdraviloma Zometa in Aclasta.
Because Zoledronic Acid Hospira is given by infusion and contains the same active substance as the reference medicines, its benefits and risks are taken as being the same as the reference medicines'. 
Ker se zdravilo Zoledronska kislina Hospira daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčni zdravili, so tveganja in koristi enaki kot pri referenčnih zdravilih.
What measures are being taken to ensure the safe and effective use of Zoledronic Acid Hospira? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zoledronska kislina Hospira?
See the package leaflet for full details. 
Za podrobnejše informacije glejte navodilo za uporabo.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic Acid Hospira, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Zoledronska kislina Hospira in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
A risk management plan has been developed to ensure that Zoledronic Acid Hospira is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Zoledronska kislina Hospira je bil pripravljen načrt obvladovanja tveganj.
Zoledronic Acid Hospira is a ‘generic' and a ‘hybrid' medicine. 
Zdravilo Zoledronska kislina Hospira je „generično“ in „hibridno“ zdravilo.
What are the benefits and risks of Zoledronic Acid Hospira? 
Kakšne so koristi in tveganja, povezani z zdravilom Zoledronska kislina Hospira?
For the treatment of Paget's disease of the bone, Zoledronic Acid Hospira is given as one infusion lasting at least 15 minutes. 
Za zdravljenje Pagetove bolezni kosti se zdravilo Zoledronska kislina Hospira daje kot infuzija v trajanju najmanj 15 minut.
By preventing the breakdown of bones, Zoledronic Acid Hospira also helps to reduce the amount of calcium released into the blood. 
Zdravilo Zoledronska kislina Hospira s preprečevanjem razgradnje kosti pripomore tudi k znižanju ravni kalcija, ki se sprošča v kri.
Therefore, the CHMP's view was that, as for Zometa and Aclasta, the benefit outweighs the identified risks. 
Zato je menil, da njegove koristi tako kot pri zdravilih Zometa in Aclasta odtehtajo znana tveganja.
Zoledronic Acid Hospira 4 mg/5 ml concentrate and 4 mg/100 ml solution are used to prevent bone complications in adults with advanced cancer that is affecting the bone. 
Zdravilo Zoledronska kislina Hospira v obliki koncentrata 4 mg/5 ml in raztopine 4 mg/100 ml se uporablja za preprečevanje z okostjem povezanih zapletov pri odraslih z napredovalim rakom, ki prizadene kosti.
The Committee recommended that Zoledronic Acid Hospira be given marketing authorisation. 
Priporočil je, da se za zdravilo Zoledronska kislina Hospira izda dovoljenje za promet.
The reference medicine for the 4 mg/5 ml concentrate and 4 mg/100 ml solution is Zometa. 
Referenčno zdravilo za koncentrat 4 mg/5 ml in raztopino 4 mg/100 ml je zdravilo Zometa.
Zoledronic Acid Hospira is a medicine that contains the active substance zoledronic acid. 
Zoledronska kislina Hospira je zdravilo, ki vsebuje zdravilno učinkovino zoledronska kislina.
Other information about Zoledronic Acid Hospira 
Druge informacije o zdravilu Zoledronska kislina Hospira
Zoledronic Acid Hospira 5 mg/100 ml solution is used to treat Paget's disease of the bone in adults. 
Raztopina 5 mg/100 ml zdravila Zoledronska kislina Hospira se uporablja tudi za zdravljenje Pagetove bolezni kosti pri odraslih.
Zoledronic Acid Hospira zoledronic acid 
Zoledronska kislina Hospira zoledronska kislina
For the prevention of bone complications and treatment of hypercalcaemia caused by tumours, the usual dose of Zoledronic Acid Hospira is one infusion of 4 mg over at least 15 minutes. 
Običajni odmerek zdravila Zoledronska kislina Hospira za preprečevanje z okostjem povezanih zapletov in zdravljenje hiperkalciemije, ki jo povzročajo tumorji, je ena 4-miligramska infuzija v trajanju najmanj 15 minut.
The active substance in Zoledronic Acid Hospira, zoledronic acid, is a bisphosphonate. 
Zdravilna učinkovina zdravila Zoledronska kislina Hospira, zoledronska kislina, je difosfonat.
Why has Zoledronic Acid Hospira been approved? 
Zakaj je bilo zdravilo Zoledronska kislina Hospira odobreno?
No additional studies were needed as Zoledronic Acid Hospira is given by infusion and contains the same active substance as the reference medicines, Zometa and Aclasta. 
Zdravilo Zoledronska kislina Hospira se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčni zdravili, Zometa in Aclasta, zato niso bile potrebne nobene dodatne študije.
Aclasta is the reference medicine for the 5 mg/100 ml solution. 
Referenčno zdravilo za raztopino 5 mg/100 ml je zdravilo Aclasta.
How has Zoledronic Acid Hospira been studied? 
Kako je bilo zdravilo Zoledronska kislina Hospira raziskano?
What is Zoledronic Acid Hospira? 
Kaj je zdravilo Zoledronska kislina Hospira?
How is Zoledronic Acid Hospira used? 
Kako se zdravilo Zoledronska kislina Hospira uporablja?
What is Zoledronic Acid Hospira used for? 
Za kaj se zdravilo Zoledronska kislina Hospira uporablja?
How does Zoledronic Acid Hospira work? 
Kako zdravilo Zoledronska kislina Hospira deluje?
ATC vet code: QP54AA54. 
Oznaka ATC vet: QP54AA54.
Recently treated animals should not sleep with owners, especially children. 
Nedavno zdravljene živali naj ne spijo z lastniki, še posebno z otroki.
Date of first authorisation: 04/12/2013 Date of latest renewal: 24/09/2018 
Datum pridobitve dovoljenja za promet: 04/12/2013 Datum zadnjega podaljšanja dovoljenja za promet: 24/09/2018
Wash hands immediately after use. 
Po uporabi si takoj temeljito umijte roke.
External use only. 
Samo za zunanjo uporabo.
Overdose (symptoms): 
Preveliko odmerjanje (simptomi):
Treatment should not be extrapolated from one animal to the other without veterinary opinion. 
Zdravljenja se ne sme posploševati iz ene živali na drugo, brez mnenja veterinarja.
On very rare occasions, symptomatic treatment can be required. 
V zelo redkih primerih je potrebno simptomatsko zdravljenje.
Therefore, epidemiological information about current susceptibility of the target species should be taken into account in order to limit the possibility of a future selection for resistance. 
Zato je potrebno upoštevati epidemiološke podatke o trenutni občutljivosti ciljnih organizmov, da se zmanjša verjetnost nastanka kasnejše rezistence s selekcijo.
Echinococcosis represents a hazard for humans, and is a notifiable disease to the World Organisation for Animal Health (OIE). 
Ehinokokoza predstavlja nevarnost za ljudi in jo je potrebno prijaviti OIE (Svetovna Organizacija za Zdravje Živali).
Clear colourless to yellow to red/brown solution. 
Bistra brezbarvna do rumena, rdeče/rjava raztopina.
Unlike other species, fipronil sulfone is not formed in cat. 
Za razliko od drugih živalskih vrst, pri mačkah ne nastaja fipronil sulfon.
Other animals living in the same household should also be treated with a suitable product. 
Tudi druge živali ki živijo v istem gospodinjstvu, je priporočljivo zdraviti z zanje primernim zdravilom.
Any unused veterinary medicinal product or waste material derived from it should be disposed of in accordance with local requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
Avoid animals licking each other following treatment. 
Preprečite medsebojno lizanje živali po zdravljenju.
BROADLINE or empty container should not enter water courses as this may be dangerous for fish and other aquatic organisms. 
BROADLINE ali prazni vsebnik ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Praziquantel has a moderate tissue distribution, and about 64-84% of praziquantel is bound to plasma proteins. 
Prazikvantel ima zmerno distribucijo v tkiva in približno 64-84% se ga veže na proteine plazme.
(S)-methoprene, once absorbed, is very quickly metabolised and excreted. 
(S)-metopren se po absorbciji zelo hitro metabolizira in izloči iz telesa.
Per dose: Fipronil 
Na odmerek: fipronil
The average half-life for praziquantel is 3.08 days. 
Povprečna biološka razpolovna doba za prazikvantel je 3,08 dni.
4 Chemin du Calquet, 31000 Toulouse FRANCE 
4 Chemin du Calquet, 31000 Toulouse FRANCIJA
The concentrations in the hair coat of fipronil, fipronil sulfone and (S)-methoprene decrease with time but remain detectable for at least 42 days after dosing. 
Koncentracije fipronila, fipronil sulfona in (S)-metoprena v dlaki se s časom zmanjšujejo vendar ostanejo merljive vsaj 42 dni po dajanju zdravila.
For treatment against Aelurostrongylus abstrusus, a second administration one month after the initial treatment may be recommended. 
Za zdravljenje infestacije z Aelurostrongylus abstrusus je lahko priporočeno še drugo odmerjanje en mesec po prvem zdravljenju.
Avoid contact of the applicator content with the fingers. 
Izogibajte se stika vsebine aplikatorja s prsti.
Once absorbed, eprinomectin is highly bound to plasma proteins (> 99%), has low clearance from blood, and distributes well into tissues. 
Po absorbciji se eprinomektin močno veže na proteine plazme (> 99%), ima nizek clearance iz krvi in se dobro prerazporeja v tkiva.
Elimination of fleas within 24 hours. 
Odpravi bolhe v 24 urah.
It is important to apply the veterinary medicinal product to a skin area where the cat cannot lick it off: on the neck, in between shoulders. 
Pomembno je, da se zdravilo nanese na mesto na koži, kjer ga mačka ne more polizati: na vrat, med lopaticami.
These signs usually resolve spontaneously within 24 hours. 
Omenjeni znaki običajno spontano izginejo prej kot v 24 urah.
Do not smoke, drink or eat during application. 
Med dajanjem zdravila je prepovedano kaditi, piti ali jesti.
No data on the effect of bathing/shampooing on the efficacy of the veterinary medicinal product in cats is available. 
Ni podatkov o vplivu kopanja/šamponiranja na učinkovitost zdravila pri mačkah.
Avoid contact with the cat's eyes. 
Izogibajte se stiku zdravila z očmi mačke.
This results in uncontrolled activity of the central nervous system and death of insects or acarians. 
Posledica je nenadzorovano delovanje centralnega živčnega sistema in smrt insektov ali zajedavcev.
The average half-life for this compound is 4.75 days. 
Povprečna biološka razpolovna doba eprinomektina je 4,75 dni.
Transitory blindness or impaired vision have been observed in very rare cases based on post marketing safety experience. 
Prehodno slepoto ali poslabšanje vida so v zelo redkih primerih opazili v post marketinških izkušnjah o varnosti.
(S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. 
(S)-metopren je regulator rasti insektov (IGR) iz skupine analogov juvenilnih hormonov, ki zavirajo razvoj nezrelih oblik insektov.
The peak plasma concentrations of the absorbed fraction of fipronil and (S)-methoprene are reached within 8 to 9 hours. 
Največje koncentracije absorbiranih frakcij fipronila in (S)-metoprena v krvni plazmi so dosežene znotraj 8-9 ur.
To reduce re-infestation from emergence of new fleas, it is recommended that all cats in a household be treated. 
Za zmanjšanje možnosti ponovne infestacije z novimi bolhami je priporočljivo zdraviti vse mačke, ki živijo skupaj.
Opened applicators should be disposed of immediately. 
Porabljene aplikatorje takoj odvrzite.